<DOC>
	<DOCNO>NCT02436135</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , pharmacokinetics , efficacy idelalisib adult receive ruxolitinib therapy intermediate high risk primary myelofibrosis ( PMF ) , post-polycythemia vera , post-essential thrombocythemia myelofibrosis ( post-PV MF post-ET MF ) progressive relapse disease .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Idelalisib Adults Receiving Ruxolitinib Therapy Primary , Post-Polycythemia Vera , Post-Essential Thrombocythemia Myelofibrosis With Progressive Relapsed Disease</brief_title>
	<detailed_description />
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<mesh_term>Idelalisib</mesh_term>
	<criteria>Key Individuals must stable dose ruxolitinib least 4 week prior study entry Individuals PMF , postPV MF , postET MF classify high risk intermediate risk define Dynamic International Prognostic Scoring System ( DIPSS ) PMF DIPSS Plus , cytogenetics available Individuals PMF , postPV MF , postET MF receive ruxolitinib meet 2013 Revised International Working Group Myelofibrosis Research Treatment ( IWGMRT ) European Leukemia Net ( ELN ) response criterion progressive relapsed disease , modification progressive disease complete remission ( CR ) , partial remission ( PR ) , clinical improvement ( CI ) European Cooperative Oncology Group ( ECOG ) performance status â‰¤ 2 Required screen laboratory value describe protocol Willing able comply schedule visit , drug administration plan , image study , laboratory test , study procedure , study restriction include mandatory prophylaxis pneumocystis jiroveci pneumonia ( PJP ) Able understand willing sign inform consent form Key Individuals stable ruxolitinib dose 5 mg daily History prior allogeneic bone marrow progenitor cell solid organ transplantation Ongoing druginduced liver injury , alcoholic liver disease , nonalcoholic steatohepatitis , primary biliary cirrhosis , extrahepatic obstruction cause cholelithiasis , cirrhosis liver Ongoing druginduced pneumonitis Ongoing inflammatory bowel disease Ongoing alcohol drug addiction Symptomatic congestive heart failure ( New York Heart Association Classification &gt; Class II ) , unstable angina , unstable cardiac arrhythmia require medication Known hypersensitivity study investigational medicinal product ( IMP ) , metabolites , formulation excipients Unwilling unable take oral medication Unresolved nonhematologic toxicity prior therapy &gt; Common terminology Criteria Adverse Events ( CTCAE ) Grade 1 ( exception alopecia [ Grade 1 2 permitted ] ) Pregnant lactate female Cytomegalovirus ( CMV ) : Ongoing infection , treatment , prophylaxis within past 28 day NOTE : Other protocol define Inclusion/ Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>